All of the following malignancies present with osteoblastic secondaries, except
**Core Concept**
Osteoblastic metastases are characterized by the formation of new bone tissue around the site of a tumor, leading to increased bone density. This is in contrast to osteolytic metastases, which involve bone destruction and decreased bone density.
**Why the Correct Answer is Right**
Multiple myeloma is a plasma cell malignancy that typically presents with osteolytic lesions, which are characterized by bone destruction and decreased bone density. This is due to the production of various factors by the myeloma cells, including interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-Ξ±), which stimulate osteoclast activity and inhibit osteoblast function. In contrast, osteoblastic lesions are more commonly associated with tumors such as prostate cancer, which secrete factors that stimulate osteoblast activity.
**Why Each Wrong Option is Incorrect**
**Option B:** Carcinoma of the prostate is a classic example of a tumor that presents with osteoblastic metastases, due to the production of prostate-specific antigen (PSA) and other factors that stimulate osteoblast activity.
**Option C:** Carcinoma of the breast can also present with osteoblastic metastases, particularly in cases of hormone receptor-positive disease, which may stimulate osteoblast activity through the production of estrogen and other hormones.
**Option D:** Carcinoid tumors can also present with osteoblastic metastases, particularly in cases of midgut carcinoid tumors, which may produce serotonin and other substances that stimulate osteoblast activity.
**Clinical Pearl / High-Yield Fact**
When evaluating a patient with metastatic cancer, it is essential to consider the type of bone lesion present, as this can have significant implications for treatment and prognosis. Osteolytic lesions are often associated with a poorer prognosis and may require more aggressive treatment, whereas osteoblastic lesions may be more amenable to treatment with bisphosphonates and other bone-targeted therapies.
**β Correct Answer: A. Multiple myeloma**